Biotech Company Opens New Facility In Wallingford

WALLINGFORD, CT — Bio-Techne, a global biotech company, has opened a new 52,000-square-foot production and manufacturing facility in Wallingford, officials announced Tuesday.

The expansion more than doubles Bio-Techne's Wallingford facility and “provides a five-fold increase” in the company’s Ella immunoassay cartridge production capacity, according to a news release.

“Ella is an automated multiplexing immunoassay system, that enables rapid and hands-free precision biomarker detection,” officials wrote in the news release. “With increased laboratory, manufacturing, and cleanroom space, the new facility increases production capacity to 500,000 cartridges per year. This enables Bio-Techne to meet growing global demand for its reproducible immunoassays capable of delivering rapid, precision multiplexing for biomarker analysis.

“Boasting one of the largest cleanrooms in the region, the new facility increases Bio-Techne's cleanroom space to 9,500 square feet. Following extensive quality validation procedures, the facility is now fully operational.”

Read more from the news release below:

Ella assays are powered by R&D Systems, a Bio-Techne brand, the recognized 30-year global leader for high quality antibodies, proteins, and ELISA kits. Ella has a rapidly growing assay menu consisting of over 200 analytes to support research across neuroscience, cell and gene therapy, immunology, oncology and other areas of research activities. Ella, and the family of miniaturized, microfluidic cartridges, delivers precision multiplex immunoassay results, providing a robust solution for simple and reliable biomarker analysis in research and clinical applications.

"We anticipate demand for our Ella assays to continue to grow as researchers have an increasing need for the speed, precision, and efficiency advantages inherent in a hands-free immunoassay workflow," said Chuck Kummeth, President and Chief Executive Officer of Bio-Techne. "This expanded immunoassay cartridge capacity positions Bio-Techne to meet current and future global demand for automated, high-quality, extremely sensitive and highly reproducible immunoassays run on our Ella system."